Serum growth factor following primary tumor removal and the inhibition of its production by preoperative therapy.
Fisher
B
B
University of Pittsburgh, Pennsylvania 15261.
Saffer
E
E
Gunduz
N
N
Coyle
J
J
Rudock
C
C
D000818:Animals; D002064:Buserelin / Q000031:analogs & derivatives / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003470:Culture Media; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D017273:Goserelin; D006133:Growth Substances / Q000096:biosynthesis / Q000097:blood*; D066298:In Vitro Techniques; D051379:Mice; D009374:Neoplasms, Experimental / Q000097:blood* / Q000628:therapy*; D011300:Preoperative Care / Q000379:methods*; D013629:Tamoxifen / Q000627:therapeutic use; D014316:Tritium
D003470:Culture Media; D006133:Growth Substances; D013629:Tamoxifen; D017273:Goserelin; D014316:Tritium; D003520:Cyclophosphamide; D002064:Buserelin